Iovance is pricing their TiLs treatment at a wholesale acquisition cost of $515,000 per patient, the company’s interim CEO Frederick Vogt, Ph.D.
Iovance's TiLs product, Amtagvi is manufactured using immune cells from individual patients. To make the final product, a patient’s TIL cells are collected from a portion of their resected tumor and then expanded outside the body before being infused back into the patient - much like CAR-T therapy. Patients who can’t undergo surgery or those without enough resected tumor tissues won’t be eligible for the therapy.